HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ST1646

alpha(v)beta3/alpha(v)beta5 integrin antagonist; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - ST1646: 1
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - ST1646: 1

Experts

1.	Belvisi, Laura: 1 article (11/2005)
2.	Carminati, Paolo: 1 article (11/2005)
3.	Chiarucci, Ilaria: 1 article (11/2005)
4.	Ciucci, Alessandro: 1 article (11/2005)
5.	Efrati, Daniela: 1 article (11/2005)
6.	Giannini, Giuseppe: 1 article (11/2005)
7.	Lombardo, Katia: 1 article (11/2005)
8.	Manzoni, Leonardo: 1 article (11/2005)
9.	Marcellini, Marcella: 1 article (11/2005)
10.	Nico, Beatrice: 1 article (11/2005)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2005 - "Moreover, ST1646 delivery via an osmotic pump inhibited the growth and vascularization of tumor xenografts originating from the injection of alpha(v)beta3/alpha(v)beta5-expressing human ovarian carcinoma cells in nude mice. " 11/01/2005 - "Taken together, these observations indicate that ST1646 represents a dual alpha(v)beta3/alpha(v)beta5 integrin antagonist with interesting biochemical and biological features to be tested in cancer therapy."
2.	Carcinoma (Carcinomatosis) 11/01/2005 - "In addition, systemic administration of ST1646 in mice exerted a significant antiangiogenic activity on neovascularization triggered by mammary carcinoma MDA-MB435 cells implanted s.c. " 11/01/2005 - "Moreover, ST1646 delivery via an osmotic pump inhibited the growth and vascularization of tumor xenografts originating from the injection of alpha(v)beta3/alpha(v)beta5-expressing human ovarian carcinoma cells in nude mice. "

Related Drugs and Biologics

1.	integrin beta5

Related Therapies and Procedures

1.	Therapeutics